JERUSALEM, May 28, 2020 /PRNewswire/ -- Intec Pharma
Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that
the Company management will present at the Jefferies Virtual
Healthcare Conference.
Jefferies Virtual Healthcare Conference
Date: June 2 – June 4, 2020
Company Presentation: Thursday, June 4,
2020 at 4:00 pm (ET)
Presenter: Jeffrey A. Meckler, Vice
Chairman and Chief Executive Officer of Intec Pharma
Format: Corporate presentation and One-on-One Investor Meetings
Mr. Meckler's presentation will be webcast live and will be
accessible through the Events section of Intec
Pharma's website at www.intecpharma.com, where it will
also be archived for a period of time.
About Intec Pharma Ltd.
Intec Pharma is a
clinical-stage biopharmaceutical company focused on developing
drugs based on its proprietary Accordion Pill platform technology.
The Company's Accordion Pill is an oral drug delivery system that
is designed to improve the efficacy and safety of existing drugs
and drugs in development by utilizing an efficient gastric
retention and specific release mechanism. The Company's product
pipeline includes two product candidates in clinical trial stages:
Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in
late-stage Phase 3 development for the treatment of Parkinson's
disease symptoms in advanced Parkinson's disease patients, and
AP-cannabinoids, an Accordion Pill to deliver either or both of the
primary cannabinoids contained in Cannabis sativa, cannabidiol
(CBD) and tetrahydrocannabinol (THC) for various pain indications.
In addition, the Company has a research collaboration
with Merck & Co.
For more information, visit www.intecpharma.com. Intec
Pharma routinely posts information that may be important to
investors in the Investor Relations section of its website.
Intec Pharma Investor Contact:
Will O'Connor
Stern IR
+1 212-362-1200
will@sternir.com
View original
content:http://www.prnewswire.com/news-releases/intec-pharma-to-present-at-jefferies-virtual-healthcare-conference-301066816.html
SOURCE Intec Pharma Ltd.